TW202315937A - 細胞之處理方法 - Google Patents

細胞之處理方法 Download PDF

Info

Publication number
TW202315937A
TW202315937A TW111133861A TW111133861A TW202315937A TW 202315937 A TW202315937 A TW 202315937A TW 111133861 A TW111133861 A TW 111133861A TW 111133861 A TW111133861 A TW 111133861A TW 202315937 A TW202315937 A TW 202315937A
Authority
TW
Taiwan
Prior art keywords
cells
activity
thawing
concentration
solution
Prior art date
Application number
TW111133861A
Other languages
English (en)
Chinese (zh)
Inventor
原田結
米満吉和
Original Assignee
日商蓋亞生物製藥有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 日商蓋亞生物製藥有限公司 filed Critical 日商蓋亞生物製藥有限公司
Publication of TW202315937A publication Critical patent/TW202315937A/zh

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0646—Natural killers cells [NK], NKT cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/04—Preserving or maintaining viable microorganisms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Inorganic Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Biochemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dispersion Chemistry (AREA)
  • Developmental Biology & Embryology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
TW111133861A 2021-09-08 2022-09-07 細胞之處理方法 TW202315937A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2021-146461 2021-09-08
JP2021146461 2021-09-08

Publications (1)

Publication Number Publication Date
TW202315937A true TW202315937A (zh) 2023-04-16

Family

ID=85507641

Family Applications (1)

Application Number Title Priority Date Filing Date
TW111133861A TW202315937A (zh) 2021-09-08 2022-09-07 細胞之處理方法

Country Status (8)

Country Link
US (1) US20240366673A1 (https=)
EP (1) EP4400576A4 (https=)
JP (1) JPWO2023038037A1 (https=)
KR (1) KR20240063899A (https=)
CN (1) CN118103492A (https=)
AU (1) AU2022342919A1 (https=)
TW (1) TW202315937A (https=)
WO (1) WO2023038037A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2024234571A1 (en) * 2023-03-15 2025-09-25 Gaia Biomedicine Inc. Solution for suspending cells and use thereof

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS4947948B1 (https=) 1970-05-21 1974-12-18
WO2002001952A1 (fr) 2000-07-05 2002-01-10 Hiromi Wada Fluide de preservation pour cellules et tissus
JP4385158B2 (ja) 2000-12-04 2009-12-16 株式会社リンフォテック 細胞の保存液および該保存液を用いた細胞の保存方法
JP4947948B2 (ja) 2004-10-12 2012-06-06 ニプロ株式会社 細胞保存液
US20120149108A1 (en) 2009-08-19 2012-06-14 Masashige Tanabe Cell preservation method
ES2652666T3 (es) * 2011-12-22 2018-02-05 Mogam Biotechnology Institute Procedimiento de producción de linfocitos citolíticos naturales, linfocitos citolíticos naturales producidos de este modo y composición para el tratamiento de cánceres y enfermedades infecciosas que contienen los mismos
WO2013115322A1 (ja) 2012-02-02 2013-08-08 タカラバイオ株式会社 細胞の保存方法
JP5432322B2 (ja) 2012-05-08 2014-03-05 株式会社大塚製薬工場 トレハロース含有肺塞栓形成予防用哺乳動物細胞懸濁液
CN114134113A (zh) * 2012-08-13 2022-03-04 人类起源公司 自然杀伤细胞及其用途
US20180021378A1 (en) * 2014-12-31 2018-01-25 Anthrogenesis Corporation Methods of treating hematological disorders, solid tumors, or infectious diseases using natural killer cells
MY201637A (en) * 2015-10-15 2024-03-06 Celularity Inc Natural killer cells and ilc3 cells and uses thereof
JP6647240B2 (ja) 2017-05-12 2020-02-14 米満　吉和 高活性ｎｋ細胞、およびその利用
FR3074018B1 (fr) * 2017-11-27 2020-09-11 Lab Francais Du Fractionnement Procede de cryoconservation de cellules a visee therapeutique
EP3720950B1 (en) * 2017-12-05 2025-09-03 Celyad S.A. Reducing fratricide of immune cells expressing nkg2d-based receptors
JP6543375B1 (ja) 2018-03-27 2019-07-10 株式会社ガイアバイオメディシン ケモカインレセプターと細胞接着分子を発現するｃｄ３陰性細胞の集団、およびその利用
US20210267190A1 (en) * 2018-07-10 2021-09-02 Nantkwest, Inc. Cryopreservation
CN113454207A (zh) * 2018-11-30 2021-09-28 细胞结构公司 用新型芳香族化合物扩增自然杀伤细胞和ilc3细胞
JP6977969B2 (ja) * 2019-03-22 2021-12-08 株式会社ガイアバイオメディシン 免疫細胞提供システム
US11660423B2 (en) * 2019-08-28 2023-05-30 Becton, Dickinson And Company Catheter system with extendable extension tube
CN114615886A (zh) * 2019-08-29 2022-06-10 得克萨斯大学体系董事会 细胞冷冻保存培养基
JP7793284B2 (ja) 2020-03-02 2026-01-05 株式会社ガイアバイオメディシン 高活性ｎｋ細胞の処理方法
EP4173640A4 (en) * 2020-06-30 2024-08-14 GAIA BioMedicine Inc. METHOD FOR STABILIZING THE BINDING OF AN ANTIBODY ON AN NK CELL AND ASSOCIATED USE

Also Published As

Publication number Publication date
AU2022342919A1 (en) 2024-03-14
CN118103492A (zh) 2024-05-28
US20240366673A1 (en) 2024-11-07
KR20240063899A (ko) 2024-05-10
EP4400576A4 (en) 2025-10-15
WO2023038037A1 (ja) 2023-03-16
EP4400576A1 (en) 2024-07-17
JPWO2023038037A1 (https=) 2023-03-16

Similar Documents

Publication Publication Date Title
JP5820958B2 (ja) トレハロース及びデキストラン含有哺乳動物細胞移植用溶液
US10113147B2 (en) Method for producing megakaryocytes, platelets and/or thrombopoietin using mesenchymal cells
KR102784950B1 (ko) 포유동물 세포의 보존액
US20230109717A1 (en) Method for treating highly active nk cells
JPWO2014208100A6 (ja) 間葉系細胞を利用した巨核球、血小板及び／又はトロンボポエチンの製造方法
CN108220235A (zh) 一种体外活化扩增人自然杀伤（nk）细胞的方法及其专用培养体系
CN110072992A (zh) 哺乳动物细胞冷冻保存液
JP7144872B2 (ja) ヒトリンパ球細胞培養用無血清培地
WO2012124978A2 (ko) 3차원 세포배양으로 수득한 조정 배지를 유효성분으로 포함하는 허혈성 질환 치료용 약학적 조성물
TW202315937A (zh) 細胞之處理方法
EP4682242A1 (en) Solution for suspending cells, and use of same
HK40108875A (en) Method for treating cells
HK40106614A (zh) 细胞的处理方法
CN118286446B (zh) 一种细胞药物冻存制剂及其制备方法与应用
HK40083554A (en) Method for treating highly active nk cells
HK40084673A (en) Method for treating highly active nk cells
TW202132557A (zh) 包含海藻醣之血球系列細胞保存用液
WO2024097793A1 (en) Method for manufacturing therapeutic immune cells
WO2026090082A2 (en) Methods for prevention of instant blood-mediated inflammatory reaction in cell based therapeutics
WO2025154708A1 (ja) 高濃度細胞保存液及び高濃度細胞保存方法